Ladan Fazli

19.8k total citations
250 papers, 11.2k citations indexed

About

Ladan Fazli is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ladan Fazli has authored 250 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Molecular Biology, 131 papers in Pulmonary and Respiratory Medicine and 56 papers in Oncology. Recurrent topics in Ladan Fazli's work include Prostate Cancer Treatment and Research (109 papers), Ubiquitin and proteasome pathways (26 papers) and Cancer, Lipids, and Metabolism (25 papers). Ladan Fazli is often cited by papers focused on Prostate Cancer Treatment and Research (109 papers), Ubiquitin and proteasome pathways (26 papers) and Cancer, Lipids, and Metabolism (25 papers). Ladan Fazli collaborates with scholars based in Canada, United States and United Kingdom. Ladan Fazli's co-authors include Martin Gleave, Eliana Beraldi, Alan So, Amina Zoubeidi, Paul S. Rennie, Colleen C. Nelson, Antonio Hurtado‐Coll, Palma Rocchi, Michael Cox and Yuzhuo Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Ladan Fazli

245 papers receiving 11.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ladan Fazli Canada	61	6.4k	4.4k	2.9k	2.7k	1.1k	250	11.2k
Joanne Edwards United Kingdom	53	4.6k 0.7×	3.0k 0.7×	2.3k 0.8×	3.0k 1.1×	758 0.7×	264	9.1k
Samuel R. Denmeade United States	56	4.4k 0.7×	4.3k 1.0×	2.2k 0.8×	2.6k 1.0×	584 0.5×	223	9.8k
Donna M. Peehl United States	61	5.6k 0.9×	3.5k 0.8×	2.2k 0.8×	2.3k 0.9×	1.1k 1.0×	211	11.8k
Jiaoti Huang United States	72	7.3k 1.1×	8.2k 1.9×	3.8k 1.3×	4.3k 1.6×	798 0.7×	308	16.4k
Fernando Schmitt Portugal	60	5.5k 0.9×	2.7k 0.6×	4.4k 1.6×	5.3k 1.9×	606 0.6×	315	13.0k
Ilsa M. Coleman United States	46	3.8k 0.6×	4.0k 0.9×	2.2k 0.8×	2.2k 0.8×	489 0.5×	111	7.8k
Paul N. Span Netherlands	57	5.1k 0.8×	1.3k 0.3×	3.1k 1.1×	2.5k 0.9×	984 0.9×	233	9.7k
Timothy C. Thompson United States	61	5.8k 0.9×	3.9k 0.9×	2.8k 1.0×	3.2k 1.2×	2.4k 2.2×	241	11.9k
Norman M. Greenberg United States	53	5.3k 0.8×	3.4k 0.8×	1.8k 0.6×	3.1k 1.1×	668 0.6×	123	10.2k
Jahn M. Nesland Norway	53	5.5k 0.9×	3.0k 0.7×	2.3k 0.8×	4.5k 1.7×	786 0.7×	203	11.4k

Countries citing papers authored by Ladan Fazli

Since Specialization

Citations

This map shows the geographic impact of Ladan Fazli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ladan Fazli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ladan Fazli more than expected).

Fields of papers citing papers by Ladan Fazli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ladan Fazli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ladan Fazli. The network helps show where Ladan Fazli may publish in the future.

Co-authorship network of co-authors of Ladan Fazli

This figure shows the co-authorship network connecting the top 25 collaborators of Ladan Fazli. A scholar is included among the top collaborators of Ladan Fazli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ladan Fazli. Ladan Fazli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deng, Ke, Nora Pällmann, Wanja Kildal, et al.. (2025). Endoplasmic reticulum stress-driven nucleotide catabolism fuels prostate cancer. Cancer Letters. 630. 217888–217888. 1 indexed citations

Pällmann, Nora, Ke Deng, Martina Tesikova, et al.. (2021). Stress-Mediated Reprogramming of Prostate Cancer One-Carbon Cycle Drives Disease Progression. Cancer Research. 81(15). 4066–4078. 18 indexed citations

Vandekerkhove, Gillian, Jean‐Michel Lavoie, Matti Annala, et al.. (2021). Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications. 12(1). 184–184. 109 indexed citations

Nouri, Mannan, Josselin Caradec, Amy A. Lubik, et al.. (2020). Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer. Clinical Cancer Research. 26(7). 1678–1689. 29 indexed citations

Kawai, Yoshihisa, Kenjiro Imada, Shusuke Akamatsu, et al.. (2020). Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics. 19(10). 2210–2220. 12 indexed citations

Beltran, Himisha, Alexander W. Wyatt, Edmund C.P. Chedgy, et al.. (2017). Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research. 23(22). 6802–6811. 52 indexed citations

Hayashi, Tetsutaro, Kilian M. Gust, Alexander W. Wyatt, et al.. (2016). Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy. Clinical Cancer Research. 22(12). 2981–2992. 75 indexed citations

Bishop, Jennifer L., Daksh Thaper, Sepideh Vahid, et al.. (2016). The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery. 7(1). 54–71. 263 indexed citations

Li, Haolong, Ning Xie, Ruiqi Chen, et al.. (2016). UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. Cancer Research. 76(22). 6701–6711. 36 indexed citations

10.

Choi, Stephen Yiu Chuen, Hui Xue, Rebecca Wu, et al.. (2016). The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clinical Cancer Research. 22(11). 2721–2733. 79 indexed citations

11.

Lelj‐Garolla, Barbara, Masafumi Kumano, Eliana Beraldi, et al.. (2015). Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics. 14(5). 1107–1116. 43 indexed citations

12.

Han, Kyung Seok, Na Li, Peter A. Raven, et al.. (2015). Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. Molecular Cancer Therapeutics. 14(4). 1024–1034. 24 indexed citations

13.

Yamamoto, Yoshiaki, Paulo J.C. Lin, Eliana Beraldi, et al.. (2015). siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research. 21(21). 4845–4855. 57 indexed citations

14.

Shiota, Masaki, Jennifer L. Bishop, Ka Mun Nip, et al.. (2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. Cancer Research. 73(10). 3109–3119. 159 indexed citations

15.

Wu, Kaijie, Daxing Xie, Yonglong Zou, et al.. (2013). The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells. Clinical Cancer Research. 19(17). 4740–4749. 55 indexed citations

16.

Grosse, Laurent, Sophie Pâquet, Patrick Caron, et al.. (2013). Androgen Glucuronidation: An Unexpected Target for Androgen Deprivation Therapy, with Prognosis and Diagnostic Implications. Cancer Research. 73(23). 6963–6971. 39 indexed citations

17.

Kumano, Masafumi, Junya Furukawa, Masaki Shiota, et al.. (2012). Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Molecular Cancer Therapeutics. 11(8). 1661–1671. 47 indexed citations

18.

Lamoureux, François, Christian Thomas, Min-Jean Yin, et al.. (2011). A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis. Clinical Cancer Research. 17(8). 2301–2313. 47 indexed citations

19.

Snoek, Robert, Helen Cheng, Katia Margiotti, et al.. (2008). In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clinical Cancer Research. 15(1). 39–47. 109 indexed citations

20.

Zoubeidi, Amina, Anousheh Zardan, Eliana Beraldi, et al.. (2007). Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity. Cancer Research. 67(21). 10455–10465. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact